Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Am with you on STB. I also carry IRT, PSEC, and HRZN. Will take a look at the others you mentioned.
Thanks for the great info
No PR yet? Has anyone contacted their IR? Thanks
RLYP Check out @exMBB Twitter posts today from annual investors meeting if interested.
RLYP Check out @exMBB Twitter posts today from annual investors meeting if interested. Great info.
Agree with you. Last two Q's especially have shown they are executing on the path to profitability.
Anyone on the call this morning? Your reaction to Q1? I think it looks good for the year... expect to get positive EPS soon.
$MY Offer for only 50% of book value!?!
I wonder if we'll see another offer...
Ugh.. so much seems cheap out there right now, but hard to know where our overall bottom will be. I think IRT stays "cheap" because of interest rate fears, real or not.
MY appears weak on the ongoing China fears - as unfounded as they may be in relation to MY.
MY what a muted response today... Perhaps market was expecting more. Their increasing backlog and China's move to non-fossil fuels for energy prevents me from selling.
$MY Q2 report in, eps $0.08
http://finance.yahoo.com/news/reports-second-quarter-2015-unaudited-115000558.html
MY perking up a bit. Trend should be higher into the next quarterly...
Added heavily to my $MY today. I think China's market will start to calm down now as we get closer to Q2's results.
Great information, as usual, and thank you.
Looks like China's market is plunging yet again, yet the stock is a steal here assuming their global demand continues. What a conundrum for us holding or considering a purchase of MY!
MY... China announces a substantial increase in renewable energy consumption.
"During Premier Li Keqiang's visit to Paris, which will hold the UN Climate Summit, he announced that China aims to increase its renewable energy consumption to approximately 20% of the country's total energy consumption by 2020. Premier Li Keqiang also stated that the country will strive to meet its environmental goals before its previously set 2030 date."
http://seekingalpha.com/article/3307805-china-sets-its-sights-on-renewable-energy-dominance
$MY The drop to the low $2's must correspond to the situation with China's stock market. Still not selling and may add more - I think the global trend that MY is addressing is not in fact levered to China. We'll see though!!
VNCKF Victory Nickel Update...
http://www.victorynickel.ca/_resources/news/nr_2015_06_23.pdf
MY Have not added or sold since the $2.88 buys last week. I do expect it to start creeping up towards Q2 earnings, then take off after they prove what we are expecting..
$MY Added as well $2.88.
$MY looking good again today. Share price still a gift for what's ahead.
IRT at 5 year lows. Adding more on this sale.
$MY Agree with you as usual 2morrow and thanks for the updates. Keep 'em coming... I have a few trusted sources of info and a handful of them are ihub users.
I am in $MY as well about half a position. Will let it grind for a bit before buying more but expect it to start creeping back up as we get closer to the next report. It's a nice medium term investment, potentially a huge long term winner in my opinion.
These results as expected. I purchased shares at 3.16 and have more bids out in case it gets that low again. Expect it to stay weak for a few weeks at least but who knows!
Thanks 2morrow.. Always appreciate your insights.
I am hoping for a pullback on the earnings rebuy lower in the coming months.
Bailed from $bioyf/RX.v in the low 6's for not acting right, and it's down again today, after what seemed to be another great quarter.
Any takes on this?
BIOYF / RX.v on sale today after another great quarter.
Impressive results as per usual. $10 coming soon in my opinion.
Purchased $MY today based primarily on your DD, with some of my own verifications. Might take a breather for a few days/weeks but it's going higher IMO. PE way too low and huge growth opportunity in front of them.
I'll thank you now, then praise or curse you later lol !
Quoth the Raven is JBI's old Investor Relations guy!
http://quoththeravenresearch.com/2015/04/03/revealing-my-identity-and-why-im-fighting-herbalife/
(JBI is now ticker PTOI)
Quoth The Raven is Chris Irons!
http://quoththeravenresearch.com/2015/04/03/revealing-my-identity-and-why-im-fighting-herbalife/
VNCKF/NI.to Halted this morning. Wonder what's up.
VNCKF/NI.to Annual Report
http://www.victorynickel.ca/_resources/financials/2014_annual_report.pdf
Cool... Agree there could be a typical pullback after a run. I'm looking for at least double this MC in 3-6 months
Why would it do that? Big boys in at ~$20. Game-changer tech to cure many types of cancer. Market cap still wayyyy too low.
Selling overdone, on only 1,257 shares traded so far today.
PFHO lil pop today in front of annual report.
VNCKF/NI.to Victory Nickel has some interesting recent updates.
http://www.victorynickel.ca/news/
TRIL offering and updated information:
http://www.sec.gov/Archives/edgar/data/1616212/000119312515087567/d886982df1.htm
Labeling of Biosimilars: Decision this week?
http://www.raps.org/Regulatory-Focus/News/2015/03/05/21652/With-US-First-Biosimilar-Approval-Expected-This-Week-is-FDAs-Biosimilar-Labeling-Guidance-Imminent/
With US' First Biosimilar Approval Expected This Week, is FDA's Biosimilar Labeling Guidance Imminent?
The US Food and Drug Administration (FDA) quietly confirmed last week that it planned to release its long-sought biosimilars labeling guidance document sometime in 2015. But with the agency expected to approve the US' first biosimilar, Sandoz' Zarxio (filgrastim, EP2006), as early as tomorrow (6 March 2015), there's a good chance the biopharmaceutical industry won't have to wait long for the release of that guidance.
At issue is the nomenclature system by which biosimilar products will be named.
Currently, both branded and generic chemical drugs share the same nonproprietary name, also known as its International Nonproprietary Name (INN). For example, both Advil and its generics are both known by the chemical name ibuprofen. This is meant to allow healthcare practitioners to readily assess which drug products are substitutable for one another in clinical practice.
But for biosimilar products, there's a problem. Unlike chemically derived generic drugs, which are supposed to be chemically identical to the drug they reference, it is all but impossible for biosimilar drugs to be identical to the approved biologic they reference. That’s because each product is derived from slightly different cell lines and is produced using slightly different manufacturing processes. While the ultimate products are highly similar, and may even have the same effect on patients, they are nevertheless not identical.
And for some industry and patient groups, those differences are potentially concerning. Those minor differences, they say, could mean biosimilar products cause different adverse events in consumers. If biosimilars share the same INN with their reference biologics, pharmacovigilance—the practice of surveillance after a drug is approved—could be made more difficult for regulators, who might not recognize which product is causing a problem. The groups have argued that each biosimilar should have its own distinct nonproprietary name.
On the opposite side are some public advocacy groups and generics companies, who have argued the issue is a distraction. FDA is the ultimate arbiter of product safety, they say, and attempts to change the names of the products are in part intended to scare or confuse consumers about the quality of new biosimilar drugs.
A third, more mainstream view is that biosimilar products should adopt the nonproprietary name associated with the reference product, but also be accompanied by a short code—ZAR, for example—to allow for easier pharmacovigilance reporting.
Everyone, it seems, has weighed in on the issue—with the exception of FDA, that is.
But that could be about to change as early as this week. In August 2014, FDA accepted the first-ever biosimilars application (using the 351(k) pathway established under the AffordableCare Act) for approval in the US. The drug, Sandoz's monoclonal antibody Zarxio, is a biosimilar version of Amgen's Neupogen (filgrastrim).
The drug is somewhat unusual in that it has already been approved by several major global regulators, including the European Medicines Agency, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and Health Canada. That approval history has given Sandoz a wealth of data with which to placate FDA, which has taken to the drug favorably.
On 7 January 2015, an FDA advisory committee voted 14-0 in favor of approving the drug, all but assuring FDA regulators will do the same.
With FDA set to reach an approval decision on Zarxio on 8 March 2015—the company's biosimilar drug user fee date—it seems likely that the agency will accompany any biosimilar approval decision with the release of its biosimilars labeling guidance.
When asked about the expected timing of the guidance, FDA spokeswoman Sandy Walsh said only that she did not "have any update to share at this time."
Still, it's hard to imagine FDA approving a new product without knowing what it will call the product in its own press release or on the drug's label. So if biosimilar labeling issues are your bread and butter, it might behoove you to pay close attention to FDA's website over the next few days.
- See more at: http://www.raps.org/Regulatory-Focus/News/2015/03/05/21652/With-US-First-Biosimilar-Approval-Expected-This-Week-is-FDAs-Biosimilar-Labeling-Guidance-Imminent/#sthash.xGEnw9Ny.18Tk7Rak.dpuf
WFCF almost back down to pre-McDonalds partnership announcement levels. Might be a buy here imo.